Turner S and Mills S. A double-blind clinical trial on a herbal remedy for premenstrual syndrome: a case study. Complementary Therapies in Medicine 1993;1(2):73-77.
van Die, M. D., Bone, K. M., Burger, H. G., and Teede, H. J. Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial. BMC.Med.Res Methodol. 2009;9:41. View abstract.
van Die, M. D., Bone, K. M., Burger, H. G., Reece, J. E., and Teede, H. J. Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J.Altern.Complement Med. 2009;15(9):1045-1048. View abstract.
van Die, M. D., Burger, H. G., Bone, K. M., Cohen, M. M., and Teede, H. J. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause. 2009;16(1):156-163. View abstract.
van Die, M. D., Burger, H. G., Teede, H. J., and Bone, K. M. Vitex agnus-castus (Chaste-Tree/Berry) in the treatment of menopause-related complaints. J Altern.Complement Med. 2009;15(8):853-862. View abstract.
van Die, M. D., Teede, H. J., Bone, K. M., Reece, J. E., and Burger, H. G. Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause. Menopause. 2009;16(4):792-796. View abstract.
Westphal, L. M., Polan, M. L., and Trant, A. S. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clin Exp.Obstet.Gynecol. 2006;33(4):205-208. View abstract.
Westphal, L. M., Polan, M. L., Trant, A. S., and Mooney, S. B. A nutritional supplement for improving fertility in women: a pilot study. J Reprod Med. 2004;49(4):289-293. View abstract.
Whelan, A. M., Jurgens, T. M., and Naylor, H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can.J.Clin.Pharmacol. 2009;16(3):e407-e429. View abstract.
Winterhoff H, Gorkow C, and Behr B. Die Hemmung der Laktation bei Ratten als indirekter Beweis fur die Senkung von Prolaktin durch Agnus castus. Zeitschrift fur Phytotherapie 1991;12:175-179.
World Health Organization. Monographs on Selected Medicinal Plants. 2004;4
Wuttke W, Splitt G, Gorkow C, and et al. Behandlung zyklusabhangiger brustschmerzen mit einem Agnus castus-haltigen arzneimittel [Treatment of cyclical mastalgia: Results of a randomized, placebo-controlled, double-blind study]. Geburtsh.u.Frauenheilk 1997;57:569-574.
Zamani, M., Neghab, N., and Torabian, S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Med.Iran 2012;50(2):101-106. View abstract.
Aksoy AN, Gozukara I, Kucur SK. Evaluation of the efficacy of fructus agni casti in women with severe primary dysmenorrhea: a prospective comparative Doppler study. J Obstet Gynaecol Res 2014;40(3):779-84. View abstract.
Artz MB. Vitex agnus-castus. In Herbal Products: Toxicology and Clinical Pharmacology, Second Edition. Ed. Tracy TS, Kingston RL. Humana Press Inc., Totowa, NJ: 2007.
Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003;18:191-5.. View abstract.
Bahman M, Hajimehdipoor H, Bioos S, Hashem-Dabaghian F, Afrakhteh M, Tansaz M. Effect of Aslagh Capsule, a Traditional Compound Herbal Product on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Three-Arm, Open-label, Randomized, Controlled Trial. Galen Med J 2019;8:e1261. View abstract.
Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with premenstrual syndrome (PMS). Arch Gynecol Obstet 2000;264:150-3. View abstract.
Bergmann, J., Luft, B., Boehmann, S., Runnebaum, B., and Gerhard, I. [The efficacy of the complex medication Phyto-Hypophyson L in female, hormone-related sterility. A randomized, placebo-controlled clinical double-blind study]. Forsch Komplementarmed Klass Naturheilkd 2000;7(4):190-199. View abstract.
Brown D. Vitex agnus castus clinical monograph. Qtrly Rev Natural Med 1994;2:111-21.
Cahill DJ, Fox R, Wardle PG, et al. Multiple follicular development associated with herbal medicine. Hum Reprod 1994;9:1469-70. View abstract.
Csupor D, Lantos T, Hegyi P, et al. Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials. Complement Ther Med. 2019;47:102190. View abstract.
Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Saf 2005;28:319-32.. View abstract.
Dinç T, Coskun F. Comparison of fructus agni casti and flurbiprofen in the treatment of cyclic mastalgia in premenopausal women. Ulus Cerrahi Derg. 2014 Mar 1;30(1):34-8 View abstract.
Dixon-Shanies D, Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep 1999;6:1383-7.. View abstract.
Du Mee C. Vitex agnus castus. Aust J Med Herb 1993;5:63-5.
Eagon PK, Elm MS, Hunter DS, et al. Medicinal herbs: modulation of estrogen action. Era of Hope Mtg, Dept Defense; Breast Cancer Res Prog, Atlanta, GA 2000;Jun 8-11.
Eftekhari MH, Rostami ZH, Emami MJ, Tabatabaee HR. Effects of "vitex agnus castus" extract and magnesium supplementation, alone and in combination, on osteogenic and angiogenic factors and fracture healing in women with long bone fracture. J Res Med Sci. 2014 Jan;19(1):1-7. View abstract.
Gerhard II, Patek A, Monga B, et al. Mastodynon for female infertility. (abstract) Forsch Komplementarmed 1998;5:272-8. View abstract.
Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast 1999;8:175-81. View abstract.
Heirati SFD, Ozgoli G, KabodMehri R, Mojab F, Sahranavard S, Nasiri M. The 4-month effect of Vitex agnus-castus plant on sexual function of women of reproductive age: A clinical trial. J Educ Health Promot 2021;10:294. View abstract.
Hossain MM, Paul N, Sohrab MH, et al. Antibacterial activity of Vitex trifolia. Fitoterapia 2001;72:695-7. View abstract.
Hung NH, Quan PM, Satyal P, et al. Acetylcholinesterase Inhibitory Activities of Essential Oils from Vietnamese Traditional Medicinal Plants. Molecules 2022;27(20):7092. View abstract.
Jarry H, Leonhardt S., Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus Castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994;102:448-54. View abstract.
Krapfl E. Prospektiv randomisierte klinische thrapiestudie zum wirksamkeitsvergleich von Orgametril®, einem 19 nor-testosteron-derivat, versus Mastodynon®, agnus castus-haltigen alkoholischen pflanzenextrakt, bei schmerzhafter mastopathie. Dissertation 1988;
Lauritzen CH, Reuter HD, Repges R, et al. Treatment of premenstrual tension syndrome with Vitex agnus castus: Controlled-double blind versus pyridoxine. Phytomedicine 1997;4:183-9.
Liu J, Burdette JE, Sun Y, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine 2004;11:18-23. View abstract.
Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001;49:2472-9.. View abstract.
Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med 2000;9:315-20. View abstract.
Mehlhorn H, Schmahl G, Schmidt J. Extract of the seeds of the plant Vitex agnus castus proven to be highly efficacious as a repellent against ticks, fleas, mosquitoes and biting flies. Parasitol Res 2005;95:363-5. View abstract.
Meier B, Berger D, Hoberg E, et al. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 2000;7:373-81. View abstract.
Merz P, Gorkow C, Schroder A, et al. The effects of a special Agnus castus extract (BP1095el) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes 1996;104:447-53. View abstract.
Milewicz A, Gejdel E, Sworen H, et al. [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study]. Arzneimittelforschung 1993;43:752-6.. View abstract.
Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Ahmadpour P, Javadzadeh Y. Effects of Vitex agnus and flaxseed on cyclic mastalgia: a randomized controlled trial. Complement Ther Med. 2016 Feb;25:90-5. View abstract.
Mirzaee F, Fakari FR, Babakhanian M, Roozbeh N, Ghazanfarpour M. The Effectiveness of Herbal Medicines on Cyclic Mastalgia: A Systematic Review on Meta-analysis. Rev Bras Ginecol Obstet 2022;44(10):972-985. View abstract.
Molaie M, Darvishi B, Jafari Azar Z, Shirazi M, Amin G, Afshar S. Effects of a combination of Nigella sativa and Vitex agnus-castus with citalopram on healthy menopausal women with hot flashes: results from a subpopulation analysis. Gynecol Endocrinol. 2019 Jan;35(1):58-61. View abstract.
Mollazadeh S, Mirghafourvand M, Abdollahi NG. The effects of Vitex agnus-castus on menstrual bleeding: A systematic review and meta-analysis. J Complement Integr Med. 2019;17(1). pii: /j/jcim.2019.17.issue-1/jcim-2018-0053/jcim-2018-0053.xml. View abstract.
Momoeda M, Sasaki H, Tagashira E, Ogishima M, Takano Y, Ochiai K. Efficacy and safety of Vitex agnus-castus extract for treatment of premenstrual syndrome in Japanese patients: a prospective, open-label study. Adv Ther. 2014 Mar;31(3):362-73. View abstract.
Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J Pharmacopuncture 2022;25(2):106-113. View abstract.
Naseri R, Farnia V, Yazdchi K, Alikhani M, Basanj B, Salemi S. Comparison of Vitex agnus-castus extracts with placebo in reducing menopausal symptoms: A randomized double-blind study. Korean J Fam Med. 2019;40(6):362-367. View abstract.
Ohyama K, Akaike T, Hirobe C, Yamakawa T. Cytotoxicity and apoptotic inducibility of Vitex agnus-castus fruit extract in cultured human normal and cancer cells and effect on growth. Biol Pharm Bull 2003;26:10-18. View abstract.
Okuyama E, Fujimori S, Yamazaki M, Deyama T. Pharmacologically active components of viticis fructus (Vitex rotundifolia). II. The components having analgesic effects. Chem Pharm Bull (Tokyo) 1998;46:655-62. View abstract.
Ono M, Yanaka T, Yamamoto M, et al. New diterpenes and norditerpenes from the fruits of Vitex rotundifolia. J Nat Prod 2002;65:537-41. View abstract.
Ooi SL, Watts S, McClean R, Pak SC. Vitex agnus-castus for the treatment of cyclic mastalgia: A systematic review and meta-analysis. J Womens Health (Larchmt). 2020;29(2):262-278. View abstract.
Prilepskaya VN, Ledina AV, Tagiyeva AV, Revazova FS. Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome. Maturitas 2006;55 Suppl 1:S55-63.
Rattanatantikul T, Maiprasert M, Sugkraroek P, Bumrungpert A. Efficacy and safety of nutraceutical on menopausal symptoms in post-menopausal women: A randomized, double-blind, placebo-controlled clinical trial. J Diet Suppl. 2020:1-15. View abstract.
Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007;23:117-22. View abstract.
Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo-controlled study. BMJ 2001;322:134-7. View abstract.
Shin TY, Kim SH, Lim JP, et al. Effect of Vitex rotundifolia on immediate-type allergic reaction. J Ethnopharmacol 2000;72:443-50. View abstract.
Soleymanzadeh F, Mahmoodi M, Shahidi S. Effect of Vitex Agnus-Castus Ethanolic Extract on Sex Hormones in Streptozotocin-Induced Diabetic Rats. J Family Reprod Health 2020;14(2):102-105. View abstract.
Somuncu E, Solak IHA. Colonic Obstruction Secondary to Phytobezoar Caused by Vitex Agnus-Castus Seeds: A Case Report. J Coll Physicians Surg Pak 2022;32(8):S115-S117. View abstract.
Tumsutti P, Maiprasert M, Sugkraroek P, Wanitphakdeedecha R, Bumrungpert A. Effects of a combination of botanical actives on skin health and antioxidant status in post-menopausal women: A randomized, double-blind, placebo-controlled clinical trial. J Cosmet Dermatol 2022;21(5):2064-2072. View abstract.
Araghiniknam M, Chung S, Nelson-White T, and et al. Antioxidant activity of Dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sciences 1996;59:L147-L157.
Cayen, M. N. and Dvornik, D. Effect of diosgenin on lipid metabolism in rats. J Lipid Res 1979;20(2):162-174. View abstract.
Cayen, M. N., Ferdinandi, E. S., Greselin, E., and Dvornik, D. Studies on the disposition of diosgenin in rats, dogs, monkeys and man. Atherosclerosis 1979;33(1):71-87. View abstract.
Datta K, Datta SK, and Datta PC. Pharmacognostic evaluation of potential yams Dioscorea. Journal of Economic and Taxonomic Botany 1984;5:181-196.
Huai, Z. P., Ding, Z. Z., He, S. A., and Sheng, C. G. [Research on correlations between climatic factors and diosgenin content in Dioscorea zingiberensis Wright]. Yao Xue.Xue.Bao. 1989;24(9):702-706. View abstract.
Hudson t, Standish L, Breed C, and et al. Clinical and endocrinological effects of a menopausal botanical formula. Journal of Naturopathic Medicine 1997;7:73-77.
Juarez-Oropeza, M. A., Diaz-Zagoya, J. C., and Rabinowitz, J. L. In vivo and in vitro studies of hypocholesterolemic effects of diosgenin in rats. Int J Biochem 1987;19(8):679-683. View abstract.
Malinow, M. R., Elliott, W. H., McLaughlin, P., and Upson, B. Effects of synthetic glycosides on steroid balance in Macaca fascicularis. J Lipid Res 1987;28(1):1-9. View abstract.
Nervi, F., Bronfman, M., Allalon, W., Depiereux, E., and Del Pozo, R. Regulation of biliary cholesterol secretion in the rat. Role of hepatic cholesterol esterification. J Clin Invest 1984;74(6):2226-2237. View abstract.
Nervi, F., Marinovic, I., Rigotti, A., and Ulloa, N. Regulation of biliary cholesterol secretion. Functional relationship between the canalicular and sinusoidal cholesterol secretory pathways in the rat. J Clin Invest 1988;82(6):1818-1825. View abstract.
Odumosu, A. How vitamin C, clofibrate and diosgenin control cholesterol metabolism in male guinea-pigs. Int J Vitam.Nutr Res Suppl 1982;23:187-195. View abstract.
Rosenberg Zand, R. S., Jenkins, D. J., and Diamandis, E. P. Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim.Acta 2001;312(1-2):213-219. View abstract.
Uchida, K., Takase, H., Nomura, Y., Takeda, K., Takeuchi, N., and Ishikawa, Y. Changes in biliary and fecal bile acids in mice after treatments with diosgenin and beta-sitosterol. J Lipid Res 1984;25(3):236-245. View abstract.
Ulloa, N. and Nervi, F. Mechanism and kinetic characteristics of the uncoupling by plant steroids of biliary cholesterol from bile salt output. Biochim.Biophys.Acta 11-14-1985;837(2):181-189. View abstract.
Zagoya JCD, Laguna J, and Guzman-Garcia J. Studies on the regulation of cholesterol metabolism by the use of structural analogue, diosgenin. Biochemical Pharmacology 1971;20:3471-3480.
Zakharov, V. N. [Hypolipemic effect of diosponine in ischemic heart disease depending on the type of hyperlipoproteinemia]. Kardiologiia. 1977;17(6):136-137. View abstract.
Accatino L, Pizarro M, Solis N, Koenig CS. Effects of diosgenin, a plant-derived steroid, on bile secretion and hepatocellular cholestasis induced by estrogens in the rat. Hepatology 1998;28:129-40. View abstract.
Aradhana AR, Rao AS, Kale RK. Diosgenin-a growth stimulator of mammary gland of ovariectomized mouse. Indian J Exp Biol 1992;30:367-70. View abstract.
Aumsuwan P, Khan SI, Khan IA, et al. Evaluation of wild yam (Dioscorea villosa) root extract as a potential epigenetic agent in breast cancer cells. In Vitro Cell Dev Biol Anim 2015;51(1):59-71. View abstract.
Cheong JL, Bucknall R. Retinal vein thrombosis associated with a herbal phytoestrogen preparation in a susceptible patient. Postgrad Med J 2005;81:266-7.. View abstract.
Eagon PK, Elm MS, Hunter DS, et al. Medicinal herbs: modulation of estrogen action. Era of Hope Mtg, Dept Defense; Breast Cancer Res Prog, Atlanta, GA 2000;Jun 8-11.
Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.
Komesaroff PA, Black CV, Cable V, et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 2001;4:144-50.. View abstract.
Liao WL, Huang CP, Wang HP, Lei YJ, Lin HJ, Huang YC. Diosgenin, a Natural Steroidal Sapogenin, Alleviates the Progression of Diabetic Retinopathy in Diabetic Mice. In Vivo 2023;37(2):661-666. View abstract.
Lu J, Wong RN, Zhang L, et al. Comparative analysis of proteins with stimulating activity on ovarian estradiol biosynthesis from four different Dioscorea species in vitro using both phenotypic and target-based approaches: implication for treating menopause. Appl Biochem Biotechnol. 2016 Sep;180(1):79-93. View abstract.
Pengelly A, Bennett K. Appalachian plant monographs: Dioscorea villosa L., Wild Yam. Available at: https://www.frostburg.edu/fsu/assets/File/ACES/Dioscorea%20villosa%20-%20FINAL(4).pdf
Skolnick AA. Scientific verdict still out on DHEA. JAMA 1996;276:1365-7. View abstract.
Agbabiaka, T. B., Pittler, M. H., Wider, B., and Ernst, E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009;32(8):637-647. View abstract.
Al Shukri, S. H., Deschaseaux, P., Kuzmin, I. V., and Amdiy, R. R. Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer Prostatic.Dis. 2000;3(3):195-199. View abstract.
Aliaev, IuG, Vinarov, A. Z., Lokshin, K. L., and Spivak, L. G. [Efficiency and safety of prostamol-Uno in patients with chronic abacterial prostatitis]. Urologiia. 2006;(1):47-50. View abstract.
Anceschi, R., Bisi, M., Ghidini, N., Ferrari, G., and Ferrari, P. Serenoa repens (Permixon(R)) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia. Minerva Urol.Nefrol. 2010;62(3):219-223. View abstract.
Anonymous. Effectiveness of lipidosterol extract Serenoa repens (Permixon) in patients with prostatic hyperplasia. Urologiia. 2002;(1):23-25. View abstract.
Authie D and Cauquil J. Appreciation de l'efficacite de permixon en pratique quotidienne. [Appreciation of the in practice daily effectiveness of permixon]. C R Ther Pharmacol Clin 1987;5(56):4-13.
Bach D and Ebeling L. Long-term drug treatment of benign prostatic hyperplasia--results of a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomed 1996;3:105-111.
Bauer, H. W., Casarosa, C., Cosci, M., Fratta, M., and Blessmann, G. [Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study]. MMW.Fortschr.Med 6-24-1999;141(25):62. View abstract.
Bertaccini, A., Giampaoli, M., Cividini, R., Gattoni, G. L., Sanseverino, R., Realfonso, T., Napodano, G., Fandella, A., Guidoni, E., Prezioso, D., Galasso, R., Cicalese, C., Scattoni, V., Armenio, A., Conti, G., Corinti, M., Spasciani, R., Liguori, G., Lampropoulou, N., and Martorana, G. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project. Arch.Ital.Urol.Androl 2012;84(3):117-122. View abstract.
Boccafoschi C and Annoscia S. Confronto fra estratto di Serenoa repens e placebo mediante prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983;50(6):1257-1268.
Boccafoschi C, Annoscia S. Confronto fra estratto di Serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983;50:1257-1268.
Braeckman J, Bruhwyler J, Vandekerckhove K, and et al. Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytother Res 1997;11:558-563.
Braeckman J, Denis L, de Leval J, and et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997;9:247-259.
Braeckman J. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. European Journal of Clinical Research. 1997;9:247-259.
Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Current Therapeutic Research 1994;55(7):776-785.
Breu, W., Hagenlocher, M., Redl, K., Tittel, G., Stadler, F., and Wagner, H. [Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism]. Arzneimittelforschung 1992;42(4):547-551. View abstract.
Breza, J., Kliment, J., Valansky, L., and et al. Prostamol Uno (Alcohol extract of the fruits of
Buck, A. C. Phytotherapy for the prostate. Br J Urol 1996;78(3):325-336. View abstract.
Cai, T., Mazzoli, S., Bechi, A., Addonisio, P., Mondaini, N., Pagliai, R. C., and Bartoletti, R. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int.J Antimicrob.Agents 2009;33(6):549-553. View abstract.
Carreras JO. Novel treatment with a hexane extract of Serenoa repens in the treatment of benign prostatic hypertrophy. Archiv Esp de Urolog 1987;40:310-313.
Casarosa, C., Cosci, di Coscio, and Fratta, M. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther 1988;10(5):585-588. View abstract.
Casner, P. R. Saw palmetto for benign prostatic hyperplasia. N Engl.J Med 5-4-2006;354(18):1950-1951. View abstract.
Champault, G., Bonnard, A. M., Cauquil, J., and Patel, J. C. [Medical treatment of prostatic adenoma. Controlled trial: PA 109 vs placebo in 110 patients]. Ann Urol (Paris) 1984;18(6):407-410. View abstract.
Chan, J. M., Elkin, E. P., Silva, S. J., Broering, J. M., Latini, D. M., and Carroll, P. R. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology 2005;66(6):1223-1228. View abstract.
Cirillo-Marucco E, Pagliarulo A, Tritto G, and et al. L'estratto di Serenoa repens (Permixon) nel trattamento precoce dell'ipertrofia prostatica . Urologia 1983;50(6):1269-1277.
Comar OB and Di Rienzo A. Mepartricina versus Serenoa repens: studio sperimentale doppio cieco su 20 casi di iperplasia prostatica benigna. Riv Ital Biol Med 1986;6(2):122-125.
Cukier J, Ducassou J Le Guillou M Leriche A Lobel B Toubol J. [Permixon versus placebo; resultats d'une étude multicentrique]. Comptes Rendus deTherapeutique et de Pharmacologie Clinique. 1985;4:15-21.
Cukier J, Ducassou J, Le Guillou M, and et al. Permixon versus placebo; resultats d'une etude multicentrique. C R Ther Pharmacol Clin 1985;4(25):15-21.
Debruyne, F., Boyle, P., Calais, da Silva, Gillenwater, J. G., Hamdy, F. C., Perrin, P., Teillac, P., Vela-Navarrete, R., Raynaud, J. P., and Schulman, C. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]. Prog.Urol. 2004;14(3):326-331. View abstract.
Debruyne, F., Koch, G., Boyle, P., Da Silva, F. C., Gillenwater, J. G., Hamdy, F. C., Perrin, P., Teillac, P., Vela-Navarrete, R., and Raynaud, J. P. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. Prog.Urol. 2002;12(3):384-392. View abstract.
Dedhia, R. C. and McVary, K. T. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J.Urol. 2008;179(6):2119-2125. View abstract.
Descotes J, Rambeaud J, Deschaseaux P, and et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995;9(5):291-297.
Descotes JL, Rambeaud JJ Deschaseaux P Faure G. Placebo controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation. 1995;5:291-297.
Di Silverio F, Monti S, Sciarra A, and et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37(2):77-83.
Di Silverio F, Sciarra A, D'Eramo G, and et al. Zonal distribution of androgens and epidermal growth factor (EGF) in human BPH tissue: responsiveness to flutamide, finasteride, and Serenoa repens administration. Brit J Urol 1997;80(Suppl 2):214.
Dimitrakov, J. D. Saw palmetto for benign prostatic hyperplasia. N Engl.J Med 5-4-2006;354(18):1950-1951. View abstract.
Djavan, B., Fong, Y. K., Chaudry, A., Reissigl, A., Anagnostou, T., Bagheri, F., Waldert, M., Fajkovic, H., Marihart, S., Harik, M., Spaller, S., and Remzi, M. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. World J Urol. 2005;23(4):253-256. View abstract.
Elghamry, M. I. and Hansel, R. Activity and isolated phytoestrogen of shrub palmetto fruits (Serenoa repens Small), a new estrogenic plant. Experientia 8-15-1969;25(8):828-829. View abstract.
Emili E, Lo Cigno M Petrone U. [Risultati clinici su un nuovo farmaco nella terapia dell'ipertofia della prostata (Permixon)]. Urologia. 1983;50:1042-1048.
Emili E, Lo Cigno M, and Petrone U. Risultati clinici su un nuovo farmaco nella terapia dell'ipertrofia della prostata (Permixon). Urologia 1983;50(5):1042-1048.
Engelmann, U., Walther, C., Bondarenko, B., Funk, P., and Schlafke, S. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222-229. View abstract.
Epstein J, Partin A, Simon I, and et al. Prostate tissue effects of saw palmetto extract in men with symptomatic BPH. J Urol 1999;161(4S):362.
Flamm, J., Kiesswetter, H., and Englisch, M. [An urodynamic study of patients with benign prostatic hypertrophy treated conservatively with phytotherapy or testosterone (author's transl)]. Wien.Klin.Wochenschr. 9-28-1979;91(18):622-627. View abstract.
Foroutan F. Wirksamkeit und vertraglichkeit von permixon bei einem grosseren patientenkollektiv (592 patienten) unter praxisbedingungen. J Urol Urogynakol 1997;2:17-21.
Gabric V and Miskic H. Behandlung des benignen Prostataadenoms und der chronischen Prostatitis. Placebokontrollierte randomisierte doppelblindstudie mit Prostagutt. Therapiewoche 1987;37:1775-1788.
Gabric V, Miskic H. [Behandlung des benignen prostata-adenoms und der chronischen prostatatitis]. Therapiewoche. 1987;37:1775-1788.
Gerber, G. S., Kuznetsov, D., Johnson, B. C., and Burstein, J. D. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58(6):960-964. View abstract.
Giannakopoulos, X., Baltogiannis, D., Giannakis, D., Tasos, A., Sofikitis, N., Charalabopoulos, K., and Evangelou, A. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. Adv.Ther 2002;19(6):285-296. View abstract.
Giulianelli, R., Pecoraro, S., Sepe, G., Leonardi, R., Gentile, B. C., Albanesi, L., Brunori, S., Mavilla, L., Pisanti, F., Giannella, R., Morello, P., Tuzzolo, D., Coscione, M., Galasso, F., D'Angelo, T., Ferravante, P., Morelli, E., and Miragliuolo, A. Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation. Arch.Ital.Urol.Androl 2012;84(2):94-98. View abstract.
Glemain, C. Coulange F. N. Grapin et al. No benefit in combining tamsulosin with Serenoa repens versus tamsulosin alone on storage/filling and voiding lower urinary tract symptoms. J Urol, 2002;167 (suppl 4)(Abstract 1486):374.
Glemain, P., Coulange, C., Billebaud, T., Gattegno, B., Muszynski, R., and Loeb, G. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial]. Prog.Urol. 2002;12(3):395-403. View abstract.
Goepel, M., Dinh, L., Mitchell, A., Schafers, R. F., Rubben, H., and Michel, M. C. Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo? Prostate 2-15-2001;46(3):226-232. View abstract.
Greca P and Volip R. Experience with a new drug in the medical treatment of prostatic adenoma. Urologia 1985;52:532-535.
Groom, S. N., Johns, T., and Oldfield, P. R. The potency of immunomodulatory herbs may be primarily dependent upon macrophage activation. J Med Food 2007;10(1):73-79. View abstract.
Hanaka, M., Yoshii, C., Yatera, K., Ito, C., Chojin, Y., Nagata, S., Yamasaki, K., Nishida, C., Kawanami, T., Kawanami, Y., Ishimoto, H., and Mukae, H. [A case of rhabdomyolysis caused by saw palmetto of healthy foods]. J.UOEH. 6-1-2012;34(2):193-199. View abstract.
Hizli, F. and Uygur, M. C. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int.Urol.Nephrol. 2007;39(3):879-886. View abstract.
Hostanska, K., Suter, A., Melzer, J., and Saller, R. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res 2007;27(2):873-881. View abstract.
Hutchison, A., Farmer, R., Verhamme, K., Berges, R., and Navarrete, R. V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007;51(1):207-215. View abstract.
Iehle, C., Delos, S., Guirou, O., Tate, R., Raynaud, J. P., and Martin, P. M. Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54(5-6):273-279. View abstract.
Iguchi, K., Okumura, N., Usui, S., Sajiki, H., Hirota, K., and Hirano, K. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001;47(1):59-65. View abstract.
Ishii, K., Usui, S., Sugimura, Y., Yamamoto, H., Yoshikawa, K., and Hiran, K. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 2001;24(2):188-190. View abstract.
Kondas, J., Philipp, V., and Dioszeghy, G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol.Nephrol. 1996;28(6):767-772. View abstract.
Kul'chavenia, E. V., Breusov, A. A., Brizhatiuk, E. V., and Kholtobin, D. P. [Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections]. Urologiia. 2010;(6):55-58. View abstract.
Lapi, F., Gallo, E., Giocaliere, E., Vietri, M., Baronti, R., Pieraccini, G., Tafi, A., Menniti-Ippolito, F., Mugelli, A., Firenzuoli, F., and Vannacci, A. Acute liver damage due to Serenoa repens: a case report. Br.J.Clin.Pharmacol. 2010;69(5):558-560. View abstract.
Lobelenz J. [Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). klinische prufung im stadium I und II]. Therapeutikon. 1992;6(1-2):34-37.
Löbelenz J. Extractum Sabal fructus bei benigner Prostatahyperplasie (BPH): Klinische Prüfung im Stadium I und II. Therapeutikon 1992;6(1-2):34, 37.
Lopatkin, N. A., Sivkov, A. V., Medvedev, A. A., Walter, K., Schlefke, S., Avdeichuk, IuI, Golubev, G. V., Mel'nik, K. P., Elenberger, N. A., and Engelman, U. [Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial]. Urologiia. 2006;(2):12, 14-12, 19. View abstract.
MacDonald, R., Tacklind, J. W., Rutks, I., and Wilt, T. J. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU.Int. 2012;109(12):1756-1761. View abstract.
Magri, V., Trinchieri, A., Montanari, E., Del Nero, A., Mangiarotti, B., Zirpoli, P., de Eguileor, M., Marras, E., Ceriani, I., Vral, A., and Perletti, G. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. Arch Ital Urol Androl 2007;79(2):84-92. View abstract.
Magri, V., Trinchieri, A., Pozzi, G., Restelli, A., Garlaschi, M. C., Torresani, E., Zirpoli, P., Marras, E., and Perletti, G. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob.Agents 2007;29(5):549-556. View abstract.
Mandressi A, Tarallo U, Maggioni A, and et al. Terapia medica dell'adenoma prostatico: confronto della efficacia del'estratto di serenoa repens (Permixon) versus l'estratto di pigeum africanum e placebo. Valutazione in doppio cieco. Urologia 1983;50(4):752-757.
Mandressi A. Treatment of uncomplicated benign prostatic hypertrophy (BPH) by an extract of Serenoa repens: clinical results. J Endocrinol Invest 1987;10 (suppl 2):49.
Mandressi S, Tarallo U Maggioni A Tombolini P Rocco F Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon) compared to that of the extract of Pygeum africanum and a placebo. Urologia. 1983;50(4):752-758.
Mantovani, F. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. Minerva Urol.Nefrol. 2010;62(4):335-340. View abstract.
Mattei FM, Capone M Acconcia A. [Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme]. TW Urologie Nephrologie. 1990;2:346-350.
Mattei FM, Capone M, and Acconcia A. Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme. TW Urol Nephrol 1990;2(5):346-350.
Medvedev, A. A., Siniakova, L. A., and Zaitsev, A. V. [Prostaplant treatment of benign prostatic hyperplasia]. Urologiia 2000;(4):13-15. View abstract.
Metzker H, Kieser M Holscher U. [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B. 1996;36(4):292-300.
Metzker H, Kieser M, and Hölscher U. Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH). Urologe 1996;36(4):292-300.
Miroddi, M., Carni, A., Mannucci, C., Moleti, M., Navarra, M., and Calapai, G. Hot flashes in a young girl: a wake-up call concerning Serenoa repens use in children. Pediatrics 2012;130(5):e1374-e1376. View abstract.
Mitropoulos D, Kiroudi A, Mitsogiannis I, and et al. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cells accumulation and glandular epithelium trophism in the rat prostate. J Urol 1999;161(4S):362.
Mohanty NK, Jha RJ, and Dutt C. Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic grade I to grade II benign prostatic hyperplasia (BPH). Indian J Urol 1999;16(1):26-31.
Morganti P, Fabrizi G, James B, and et al. Effect of gelatin-cystine and Serenoa repens extract on free radicals level and hair growth. J Appl Cosmetol 1998;16:57-64.
Morgia, G., Mucciardi, G., Gali, A., Madonia, M., Marchese, F., Di, Benedetto A., Romano, G., Bonvissuto, G., Castelli, T., Macchione, L., and Magno, C. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol.Int. 2010;84(4):400-406. View abstract.
Neff, K. D., Sandoval, H. P., Fernandez de Castro, L. E., Nowacki, A. S., Vroman, D. T., and Solomon, K. D. Factors associated with intraoperative floppy iris syndrome. Ophthalmology 2009;116(4):658-663. View abstract.
Pannunzio E, D'Ascenzo R, Giardinetti F, and et al. Serenoa repens vs. gestonorone caproato nel trattamento dell'ipertrofia prostatica benigna. Studio randomizzato. Urologia 1986;53(5):696-705.
Paoletti PP, Francalanci R, Tenti S, and et al. Medical treatment of prostatic hypertrophy. Experience with Serenoa repens extract. Urologia 1986;53:182-187.
Paubert-Braquet M, Raynaud JP, and Braquet PG. Permixon [lipid sterolic extract of
Paubert-Braquet, M., Cousse, H., Raynaud, J. P., Mencia-Huerta, J. M., and Braquet, P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33(3):340-347. View abstract.
Paubert-Braquet, M., Richardson, F. O., Servent-Saez, N., Gordon, W. C., Monge, M. C., Bazan, N. G., Authie, D., and Braquet, P. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone- induced experimental prostate enlargement in the rat. Pharmacol Res 1996;34(3-4):171-179. View abstract.
Pavone, C., Abbadessa, D., Tarantino, M. L., Oxenius, I., Lagana, A., Lupo, A., and Rinella, M. [Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients]. Urologia. 2010;77(1):43-51. View abstract.
Pecoraro, S., Annecchiarico, A., Gambardella, M. C., and Sepe, G. [Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate]. Minerva Urol.Nefrol. 2004;56(1):73-78. View abstract.
Plosker, G. L. and Brogden, R. N. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9(5):379-395. View abstract.
Pytel, Y. A., Vinarov, A., Lopatkin, N., Sivkov, A., Gorilovsky, L., and Raynaud, J. P. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv.Ther 2002;19(6):297-306. View abstract.
Redecker KD. [Sabal extract WS 1473 in benign prostatic hyperplasia]. Extracta Urologica 1998;21(3):23-25.
Reece Smith H, Memon A, Smart C, and et al. The value of Permixon in benign prostatic hypertrophy. Brit J Urol 1986;58(1):36-40.
Rhodes, L., Primka, R. L., Berman, C., Vergult, G., Gabriel, M., Pierre-Malice, M., and Gibelin, B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 1993;22(1):43-51. View abstract.
Roveda S and Colombo P. Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160mg or rectal capsules 640mg. Arch Med Interna 1994;46(2):61-75.
Savel'eva KV, Kachanova MV Pavlov VN Kazikhinurov RA Frolov MY Mukhin AB Udut VV Yurmazov ZA Dugina YL Sergeeva SA Epshtein OI. Clinical study of the efficiency and safety of afala in patients with benign prostatic hyperplasia. Bull Exp Biol Med. 2009;148(2):305-307.
Scaglione, F., Lucini, V., Pannacci, M., Dugnani, S., and Leone, C. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur.Rev.Med.Pharmacol.Sci. 2012;16(5):569-574. View abstract.
Schneider, H. J., Honold, E., and Masuhr, T. [Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices]. Fortschr Med 1-30-1995;113(3):37-40. View abstract.
Semino A, Ortega L, Cobo G, and et al. [Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens.]. Archivos Espanoles de Urologia 1992;45(3):211-213.
Venkateswaran S, Declet-Bauzo R, Shodeinde M, Gilford P. Postoperative Retroperitoneal Hematoma: A Case of Saw Palmetto and the Importance of Primary Care Intervention. HCA Healthc J Med 2020;1(5):279-282. View abstract.
Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003;92:267-70.. View abstract.
Wilt T, Ishani A, Stark G, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;(2):CD001423. View abstract.
Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604-9. View abstract.
Wyatt GK, Sikorskii A, Safikhani A, McVary KT, Herman J. Saw palmetto for symptom management during radiation therapy for prostate cancer. J Pain Symptom Manage. 2016;51(6):1046-54. doi: 10.1016/j.jpainsymman.2015.12.315. View abstract.
Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005;11:433-9. View abstract.
Yamada S, Shirai M, Ono K, Kageyama S. Beneficial effects of saw palmetto fruit extract on urinary symptoms in Japanese female subjects by a multicenter, randomized, double-blind, placebo-controlled study. Nutrients 2022;14(6):1190. View abstract.
Zhang K, Guo RQ, Chen SW, et al. The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial. World J Urol 2021;39(9):3489-3495. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.